PE Deals Logo
PE Deals UK M&A Brokers & VC
Back to Deals
Forge Genetics
Value Undisclosed

Forge Genetics

N/A if unsure
Cross-border
Pharmaceutical Published 13 March 2026

Summary

Forge Genetics has secured a licensing agreement with global pharmaceutical company AbbVie for its genome editing technology.

Summary of transaction details:

  • Value: N/A
  • Sector: Pharmaceutical
  • Advisor: N/A
  • Key Entities: Forge Genetics, AbbVie
  • Location: East Midlands

Note: The partnership follows successful proof-of-concept work where Forge Genetics' technology demonstrated its potential in a limited field.

Lead Investor / Acquirer

AbbVie

Advising Broker

Undisclosed Firm

Original Source

View the original press release or news article describing this transaction in full.

Read Original Post

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Sign in to unlock AI Lenses

Sign in

Sign in to submit corrections

Free to all registered users.